化痰通络法联合尿激酶溶栓治疗急性脑梗死临床研究

Clinical study on the therapy for acute cerebral infarction with Huatan Tongluo combined with urokinase thrombolysis

[目的]评价中药联合尿激酶溶栓治疗急性脑梗死的临床疗效,为脑梗死急性期临床综合治疗方案提供依据。[方法]将符合纳入标准的急性脑梗死患者60例,随机分为试验组和对照组。在常规治疗的基础上,试验组采用化痰通络法联合尿激酶治疗,对照组采用尿激酶治疗。两组尿激酶连续给药3d,试验组化痰通络中药汤剂,1剂/d,治疗14d。分别记录两组患者治疗前后的美国国立卫生研究院卒中量表(NIHSS)评分、Barthel指数评分、改良Rankin指数评分变化情况。[结果]化痰通络法联合尿激酶组在NIHSS评分、Barthel指数评分改善方面均优于尿激酶组(P<0.05);在残障(改良Rankin指数)评估方面,统计学处理两者虽无差异(P>0.05),但化痰通络法联合尿激酶组呈现出一定优势。[结论]1)化痰通络法联合尿激酶溶栓可改善脑梗死患者的神经功能,提高患者日常生活能力和社会活动参与能力,提升患者生存质量。2)中药联合尿激酶溶栓治疗急性脑梗死疗效确切,且优于单纯尿激酶溶栓治疗。

[Objective] To evaluate the therapeutic effect of the of Chinese medicine combined with urokinase on acute cerebral infarction. [Methods] Based on the enrolled criteria sixty patients with acute cerebral infarction were randomly divided into the experiment and the control groups. Both groups were continuously given urokinase for three days. After that, the Huatan Tongluo （resolving phlegm and dredging collateral） medication was administered only in the experiment group for 14 days one dose a day. The NIHSS, Barthel Index（BI）and modified Rankin Scale （mRS） were analyzed for all subjects. [Results] The experiment group showed superiority in improving the scores of NIHSS and Barthel index compared to the control group （P〈0.05）; Based on the evaluating of MRS the experiment group was superior to the control group although no significant statistic difference was found （P〉0.05）. [Conclusion] The Huatan Tongluo combined wilh urokinase can improve the neural function and the living quality of the patients with cerebral infarction. It is believed that the Chinese medicine combined with urokinase is effective on patients with acute cerebral infarction and is superior to the therapy of urokinase only.